10 hasil
Menampilkan 1–10 · 0,15 detik · RSS
Diabetes Obesity and Metabolism
Scopus
ISSN 1462-8902 · Wiley · 10 artikel di indeks
-
Artikel Jurnal Teks lengkap
Changes in lean body mass with glucagon‐like peptide ‐1‐based therapies and mitigation strategies
Weight loss induced by glucagon-like peptide-1 receptor agonists (GLP-1RAs) and dual glucagon-like peptide-1 receptor (GLP-1R)/glucose-dependent insulinotropic polypeptide receptor agonists is coming closer to the magnitudes achieved with surgery. However, with greater weight loss there is concern…
-
Artikel Jurnal Teks lengkap
Prevalence of obesity and associated complications in China: A cross‐sectional, real‐world study in 15.8 million adults
AIM: To evaluate the prevalence of overweight/obesity and associated complications from a large, cross-sectional, nationwide database in China. MATERIALS AND METHODS: Data were obtained from 519 Meinian health check-up centres across 243 cities. Eligible participants were aged ≥18 years, with a…
-
Artikel Jurnal
Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension
AIM: To explore changes in body weight and cardiometabolic risk factors after treatment withdrawal in the STEP 1 trial extension. MATERIALS AND METHODS: with ≥ 1 weight-related co-morbidity) without diabetes to 68 weeks of once-weekly subcutaneous semaglutide 2.4 mg (including 16 weeks of dose…
-
Artikel Jurnal Teks lengkap
Semaglutide for the treatment of overweight and obesity: A review
Obesity is a chronic, relapsing disease associated with multiple complications and a substantial morbidity, mortality and health care burden. Pharmacological treatments for obesity provide a valuable adjunct to lifestyle intervention, which often achieves only limited weight loss that is difficult…
-
Artikel Jurnal
The evolving story of incretins ( GIP and GLP ‐1) in metabolic and cardiovascular disease: A pathophysiological update
Abstract The incretin hormones glucose‐dependent insulinotropic polypeptide (GIP) and glucagon‐like peptide‐1 (GLP‐1) have their main physiological role in augmenting insulin secretion after their nutrient‐induced secretion from the gut. A functioning entero‐insular (gut‐endocrine pancreas) axis is…
-
Artikel Jurnal
COVID ‐19 infection may cause ketosis and ketoacidosis
The present study included 658 hospitalized patients with confirmed COVID-19. Forty-two (6.4%) out of 658 patients presented with ketosis on admission with no obvious fever or diarrhoea. They had a median (interquartile range [IQR]) age of 47.0 (38.0-70.3) years, and 16 (38.1%) were men. Patients…
-
Artikel Jurnal Teks lengkap
Newly diagnosed diabetes is associated with a higher risk of mortality than known diabetes in hospitalized patients with COVID ‐19
AIM: To evaluate the association between different degrees of hyperglycaemia and the risk of all-cause mortality among hospitalized patients with COVID-19. MATERIALS AND METHODS: In a retrospective study conducted from 22 January to 17 March 2020, 453 patients were admitted to Union Hospital in…
-
Artikel Jurnal Teks lengkap
The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity
Abstract Aim To investigate the effects of once‐weekly subcutaneous (s.c.) semaglutide 2.4 mg on gastric emptying, appetite, and energy intake in adults with obesity. Materials and Methods A double‐blind, parallel‐group trial was conducted in 72 adults with obesity, randomized to once‐weekly s.c…
-
Artikel Jurnal Teks lengkap
An updated overview of diabetic nephropathy: Diagnosis, prognosis, treatment goals and latest guidelines
Diabetic nephropathy (DN) is a major healthcare challenge. It occurs in up to 50% of those living with diabetes, is a major cause of end-stage kidney disease (ESKD) that requires treatment with dialysis or renal transplantation, and is associated with significantly increased cardiovascular…
-
Artikel Jurnal Teks lengkap
Heart failure and chronic kidney disease manifestation and mortality risk associations in type 2 diabetes: A large multinational cohort study
AIMS: To examine the manifestation of cardiovascular or renal disease (CVRD) in patients with type 2 diabetes (T2D) initially free from CVRD as well as the mortality risks associated with these diseases. METHODS: Patients free from CVRD were identified from healthcare records in England, Germany…